Tacrolimus-Resistant SARS-CoV-2-Specific T Cell Products to Prevent and Treat Severe COVID-19 in Immunosuppressed Patients

By
Justin.choi
-
0
34
Scientists proposed adoptive transfer of SARS-CoV-2-specific T cells made resistant to a common immunosuppressant, Tacrolimus, for optimized performance in the immunosuppressed patient.
[Molecular Therapy-Methods & Clinical Development]

Sorry, but the selected Zotpress account can't be found.

AbstractFull ArticleGraphical Abstract